Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Sturge Weber Syndrome (SWS) is a rare disease that affects the patient's brain and causes
benign (non-cancerous) tumors to grow in the brain. One of the symptoms of SWS is epilepsy.
People with epilepsy have seizures. Some patients may also have eye problems and a red mark
on their facial skin.
This study is being done to find out if the study drug, everolimus, is safe and has helpful
effects in patients with SWS who have seizures and are not responding to their current
anti-epileptic medication.
The study drug, everolimus (Afinitor®), is supplied by Novartis Pharmaceuticals Corporation.